- Home
- BSM vs CLDX Comparison
BSM vs CLDX Comparison
Compare BSM & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- CLDX
- Stock Information
- Founded
- BSM 1876
- CLDX 1983
- Country
- BSM United States
- CLDX United States
- Employees
- BSM N/A
- CLDX N/A
- Industry
- BSM Oil & Gas Production
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BSM Energy
- CLDX Health Care
- Exchange
- BSM Nasdaq
- CLDX Nasdaq
- Market Cap
- BSM 3.3B
- CLDX 2.9B
- IPO Year
- BSM 2015
- CLDX 2008
- Fundamental
- Price
- BSM $15.22
- CLDX $23.55
- Analyst Decision
- BSM Buy
- CLDX Buy
- Analyst Count
- BSM 3
- CLDX 8
- Target Price
- BSM $17.50
- CLDX $64.83
- AVG Volume (30 Days)
- BSM 431.3K
- CLDX 1.1M
- Earning Date
- BSM 11-04-2024
- CLDX 11-06-2024
- Dividend Yield
- BSM 9.86%
- CLDX N/A
- EPS Growth
- BSM N/A
- CLDX N/A
- EPS
- BSM 1.64
- CLDX N/A
- Revenue
- BSM $457,207,000.00
- CLDX $9,976,000.00
- Revenue This Year
- BSM N/A
- CLDX N/A
- Revenue Next Year
- BSM $3.60
- CLDX N/A
- P/E Ratio
- BSM $9.30
- CLDX N/A
- Revenue Growth
- BSM N/A
- CLDX 128.55
- 52 Week Low
- BSM $13.94
- CLDX $23.49
- 52 Week High
- BSM $17.80
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- BSM 55.63
- CLDX 29.53
- Support Level
- BSM $14.91
- CLDX $25.56
- Resistance Level
- BSM $15.46
- CLDX $28.15
- Average True Range (ATR)
- BSM 0.27
- CLDX 1.62
- MACD
- BSM 0.04
- CLDX 0.14
- Stochastic Oscillator
- BSM 67.82
- CLDX 1.27
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.